M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer

Not Applicable

Recruiting

Conditions: Anatomic Stage I Breast Cancer AJCC v8
Anatomic Stage II Breast Cancer AJCC v8
Prognostic Stage IA Breast Cancer AJCC v8
Prognostic Stage IB Breast Cancer AJCC v8
Anatomic Stage IB Breast Cancer AJCC v8
Anatomic Stage IIB Breast Cancer AJCC v8
Prognostic Stage I Breast Cancer AJCC v8
Prognostic Stage IIA Breast Cancer AJCC v8
Invasive Breast Carcinoma
Prognostic Stage II Breast Cancer AJCC v8

Interventions: Other: Decision Aid
Other: Questionnaire Administration

First Posted Date: 2016-09-29

Last Posted Date: 2025-05-13

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 15

Registration Number: NCT02918474

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Lenvatinib and Capecitabine in Patients With Advanced Malignancies

Phase 1

Withdrawn

Conditions: Malignant Neoplasm of Breast
Malignant Neoplasms of Digestive Organs
Malignant Neoplasms of Mesothelial and Soft Tissue
Advanced Cancer
Malignant Neoplasms of Bone and Articular Cartilage
Malignant Neoplasms of Eye Brain and Other Parts of Central Nervous System
Malignant Neoplasms of Female Genital Organs
Malignant Neoplasms of Independent (Primary) Multiple Sites
Malignant Neoplasms of Urinary Tract
Malignant Neoplasms of Lip Oral Cavity and Pharynx

Interventions: Drug: Lenvatinib
Drug: Capecitabine

First Posted Date: 2016-09-26

Last Posted Date: 2017-06-26

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT02915172

Hypofractionated Vs. Conventional Regional Nodal Radiation Therapy for Patients with Invasive Breast Cancer

Phase 2

Active, not recruiting

Conditions: Invasive Breast Carcinoma
Stage I Breast Cancer AJCC V7
Stage IA Breast Cancer AJCC V7
Stage IB Breast Cancer AJCC V7
Stage II Breast Cancer AJCC V6 and V7
Stage IIA Breast Cancer AJCC V6 and V7
Stage IIB Breast Cancer AJCC V6 and V7
Stage IIIA Breast Cancer AJCC V7
Stage IIIC Breast Cancer AJCC V7

Interventions: Radiation: Hypofractionated Radiation Therapy
Other: Laboratory Biomarker Analysis
Other: Quality-of-Life Assessment
Other: Questionnaire Administration
Radiation: Radiation Therapy

First Posted Date: 2016-09-23

Last Posted Date: 2025-01-31

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 805

Registration Number: NCT02912312

Locations: 🇺🇸
MD Anderson Cancer Center (Banner), Gilbert, Arizona, United States
🇺🇸
Scripps- MD Anderson Cancer, San Diego, California, United States
🇺🇸
MD Anderson Cancer Center (Banner)- Northern Colorado, Greeley, Colorado, United States

and more 9 locations

Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma

Phase 2

Active, not recruiting

Conditions: Stage IV Cutaneous Melanoma AJCC v6 and v7
Unresectable Melanoma
Stage IIIA Cutaneous Melanoma AJCC v7
Metastatic Malignant Neoplasm in the Brain
Metastatic Melanoma
Stage III Cutaneous Melanoma AJCC v7
Stage IIIB Cutaneous Melanoma AJCC v7
Stage IIIC Cutaneous Melanoma AJCC v7

Interventions: Drug: Dabrafenib
Drug: Binimetinib
Drug: Encorafenib
Other: Laboratory Biomarker Analysis
Biological: Nivolumab
Other: Pharmacological Study
Drug: Trametinib

First Posted Date: 2016-09-22

Last Posted Date: 2025-04-27

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 52

Registration Number: NCT02910700

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Expectations Regarding Mobility and Self-Care

Active, not recruiting

Conditions: Benign Neoplasms
Malignant Neoplasms of Independent (Primary) Multiple Sites

Interventions: Behavioral: Questionnaires

First Posted Date: 2016-09-22

Last Posted Date: 2025-05-11

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 133

Registration Number: NCT02911064

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Pembrolizumab and CXCR4 Antagonist BL-8040 in Treating Patients With Metastatic Pancreatic Cancer

Phase 2

Completed

Conditions: Metastatic Pancreatic Adenocarcinoma
Recurrent Pancreatic Adenocarcinoma
Stage IV Pancreatic Cancer AJCC v6 and v7

Interventions: Drug: CXCR4 Antagonist BL-8040
Biological: Pembrolizumab
Other: Pharmacological Study

First Posted Date: 2016-09-20

Last Posted Date: 2025-02-19

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 20

Registration Number: NCT02907099

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Bosutinib in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase After Frontline TKI Failure

Phase 2

Terminated

Conditions: Blasts Under 15 Percent of Peripheral Blood White Cells
Blasts Under 15 Percent of Bone Marrow Nucleated Cells
Blasts Under 30 Percent of Bone Marrow Nucleated Cells
Blasts Under 30 Percent of Peripheral Blood White Cells
Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive